Ranbaxy Of India Said Set To Acquire India's Biovel For $110 MIllion
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories reportedly is negotiating a takeover of Biovel Life Sciences, an India-based biotech. The acquisition price is estimated at $110 million. Sources say the takeover is expected to occur soon, but neither company would comment. The proposed acquisition is expected to give Ranbaxy expanded opportunities in biotechnology drugs. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.